• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Ardelyx (ARDX) Rising Revenues Amid Growing Analyst Earnings Caution

    Simply Wall St·08/01/2026 20:33:49
    Listen to the news
    • In late July 2026, Ardelyx was reported to be on track for higher quarterly revenues and a smaller loss per share year over year, even as analysts cut their earnings estimates and flagged a negative Earnings ESP ahead of the June-quarter results.
    • This combination of improving headline metrics but increasingly cautious analyst expectations highlights a tension between operational progress and confidence in near-term earnings power.
    • We’ll now examine how this growing analyst caution on Ardelyx’s earnings outlook may influence the company’s broader investment narrative.

    AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Ardelyx Investment Narrative Recap

    To own Ardelyx today, you have to believe its focused GI and kidney franchise around tenapanor can eventually support a profitable, durable business despite current losses, reimbursement uncertainty and a concentrated product lineup. The latest expectation of higher June-quarter revenue and a smaller loss per share, alongside more cautious earnings estimates, may influence short term sentiment, but it does not materially change the central near term catalyst or the biggest risk: market access and reimbursement for XPHOZAH and IBSRELA.

    Among recent announcements, Ardelyx’s reiterated 2026 revenue guidance on 30 April 2026 stands out in this context, with management reaffirming US$410–US$430 million for IBSRELA and US$110–US$120 million for XPHOZAH. That confirmation framed the current earnings debate: analysts are now rethinking how much of that topline outlook might translate into earnings power, especially while legal and payer uncertainties around Medicare coverage for XPHOZAH and ongoing SG&A investment remain unresolved.

    Yet this optimism around revenue still sits alongside a reimbursement risk that investors should be aware of if Medicare access for XPHOZAH does not fully recover and...

    Read the full narrative on Ardelyx (it's free!)

    Ardelyx's narrative projects $1.0 billion revenue and $317.0 million earnings by 2029. This requires 34.8% yearly revenue growth and a $375.1 million earnings increase from -$58.1 million today.

    Uncover how Ardelyx's forecasts yield a $16.33 fair value, a 230% upside to its current price.

    Exploring Other Perspectives

    ARDX 1-Year Stock Price Chart
    ARDX 1-Year Stock Price Chart

    Before this earnings reset, the most optimistic analysts were penciling in about US$1.1 billion of revenue and roughly US$425.8 million of earnings by 2029, which is far more upbeat than the cautious signals implied by recent estimate cuts. If you lean toward those higher forecasts, you are effectively assuming that reimbursement and pricing risks will be contained, while the latest negative Earnings ESP hints that this consensus could shift meaningfully as new information arrives.

    Explore 6 other fair value estimates on Ardelyx - why the stock might be worth just $13.00!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.